Loading...
Loading...
Browse all stories on DeepNewz
VisitImpact of AlphaFold 3 on Google's AI market position by end of 2024
Significantly strengthens • 33%
Slightly strengthens • 33%
No significant change • 33%
Market analysis reports and AI industry rankings
Google DeepMind and Isomorphic Labs Release AlphaFold 3 for DNA, RNA; Limited to Non-Commercial Use
May 8, 2024, 03:40 PM
Google DeepMind, in collaboration with Isomorphic Labs, has unveiled AlphaFold 3, a groundbreaking AI model designed to predict the structure and interactions of biomolecules with unprecedented accuracy. This latest version extends its capabilities beyond proteins to include DNA, RNA, and small molecules, potentially revolutionizing drug discovery and biological research. The model, which has been published in Nature, is expected to enhance understanding of complex biological interactions and accelerate the development of new therapies. Despite its capabilities, access to AlphaFold 3 is restricted to non-commercial use on DeepMind's server, sparking discussions about its availability and potential impact on the field. It boasts a 50% improvement over existing methods and introduces the AlphaFold Server for enhanced accessibility, highlighting its enormous commercial value.
View original story
Significant increase in stock value • 25%
Moderate increase • 25%
No significant change • 25%
Decrease in stock value • 25%
Increase • 50%
No Change or Decrease • 50%
Significant Increase • 25%
Moderate Increase • 25%
No Change • 25%
Decrease • 25%
Significantly Strengthened • 33%
Moderately Strengthened • 34%
No Significant Change • 33%
Increase • 33%
No Change • 34%
Decrease • 33%
Stock price increases • 33%
Stock price decreases • 33%
Stock price remains stable • 34%
Significant increase • 33%
Moderate increase • 34%
No change or decrease • 33%
Remains steady • 33%
Significantly improves • 33%
Declines due to competition • 33%
Significant Increase • 33%
Moderate Increase • 34%
No Change or Decrease • 33%
Drug discovery • 25%
Genetic research • 25%
Cancer research • 25%
Antibody development • 25%
Environmental science • 33%
Genetic diseases • 33%
Agricultural biology • 33%